| ［1］ |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209–249.
|
| ［2］ |
Li Z, Lv D, Niu L, et al. The role of WNT signaling in papillary thyroid cancer: mechanisms, epigenetic regulation, therapeutic resistance, and emerging clinical strategies[J]. Pathol Res Pract, 2025, 275: 156231.
|
| ［3］ |
He Y, Sun MM, Zhang GG, et al. Targeting PI3K/Akt signal transduction for cancer therapy[J]. Sig Transduct Target Ther, 2021, 6(1): 425.
|
| ［4］ |
Voinea IA, Petrova E, Dumitru N, et al. Pathogenesis and management strategies in radioiodine-refractory differentiated thyroid cancer: from molecular mechanisms toward therapeutic approaches: A comprehensive review[J]. J Clin Med, 2024, 13(23): 7161.
|
| ［5］ |
Drilon A, Hu ZI, Lai GGY, et al. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes[J]. Nat Rev Clin Oncol, 2018, 15(3): 151–167.
|
| ［6］ |
Lan Y, Liu D, Liang B, et al. ITGA3-MET interaction promotes papillary thyroid cancer progression via ERK and PI3K/AKT pathways[J]. Ann Med, 2025, 57(1): 2483379.
|
| ［7］ |
Yehia L, Keel E, Eng C. The clinical spectrum of PTEN mutations[J]. Annu Rev Med, 2020, 71: 103–116.
|
| ［8］ |
Salim U, Kumar A, Kulshreshtha R, et al. Biogenesis, characterization, and functions of mirtrons[J]. Wires RNA, 2022, 13(1): e1680.
|
| ［9］ |
Han J, Zhang M, Nie C, et al. MiR-215 suppresses papillary thyroid cancer proliferation, migration, and invasion through the AKT/GSK-3β/Snail signaling by targeting ARFGEF1[J]. Cell Death Dis, 2019, 10(3): 195.
|
| ［10］ |
Bu Q, You F, Pan G, et al. MiR-125b inhibits anaplastic thyroid cancer cell migration and invasion by targeting PIK3CD[J]. Biomed Pharmacother, 2017, 88: 443–448.
|
| ［11］ |
Boufraqech M, Zhang L, Jain M, et al. MiR-145 suppresses thyroid cancer growth and metastasis and targets AKT3[J]. Endocr Relat Cancer, 2014, 21(4): 517–531.
|
| ［12］ |
Tan J, Li C, Ren L, et al. miR-451a suppresses papillary thyroid cancer cell proliferation and invasion and facilitates apoptosis through targeting DCBLD2 and AKT1[J]. Mol Cell Probes, 2022, 66: 101863.
|
| ［13］ |
Li J, Zhang Z, Hu J, et al. miR-1246 regulates the PI3K/AKT signaling pathway by targeting PIK3AP1 and inhibits thyroid cancer cell proliferation and tumor growth[J]. Mol Cell Biochem, 2022, 477(3): 649–661.
|
| ［14］ |
Ramírez-Moya J, Wert-Lamas L, Santisteban P. microRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN[J]. Oncogene, 2018, 37(25): 3369–3383.
|
| ［15］ |
Huang Y, Yu S, Cao S, et al. MicroRNA-222 promotes invasion and metastasis of papillary thyroid cancer through targeting protein phosphatase 2 regulatory subunit B alpha expression[J]. Thyroid, 2018, 28(9): 1162–1173.
|
| ［16］ |
Montero-Conde C, Graña-Castro O, Martín-Serrano G, et al. Hsa-miR-139–5p is a prognostic thyroid cancer marker involved in HNRNPF-mediated alternative splicing[J]. Int J Cancer, 2020, 146(2): 521–530.
|
| ［17］ |
Zheng T, Zhou Y, Xu X, et al. MiR-30c-5p loss-induced PELI1 accumulation regulates cell proliferation and migration via activating PI3K/AKT pathway in papillary thyroid carcinoma[J]. J Transl Med, 2022, 20(1): 20.
|
| ［18］ |
Tang Y, Wang J, Lian Y, et al. Linking long non-coding RNAs and SWI/SNF complexes to chromatin remodeling in cancer[J]. Mol Cancer, 2017, 16(1): 42.
|
| ［19］ |
Feng J, Zhou Q, Yi H, et al. A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145–5p to regulate AKT3[J]. Cell Death Dis, 2019, 10(6): 433.
|
| ［20］ |
Du X, Hao Y, Liu M, et al. LncRNA HOTAIR promotes cell proliferation and migration in papillary thyroid carcinoma cells by sponging miR-206/c-Met axis[J]. J Mol Histol, 2025, 56(5): 283.
|
| ［21］ |
Wen J, Wang H, Dong T, et al. STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301–3p/STAT3 axis and PI3K/AKT signalling pathway[J]. Cell Prolif, 2019, 52(2): e12569.
|
| ［22］ |
Du P, Liu F, Liu Y, et al. Linc00210 enhances the malignancy of thyroid cancer cells by modulating miR-195–5p/IGF1R/Akt axis[J]. J Cell Physiol, 2020, 235(2): 1001–1012.
|
| ［23］ |
Zhang L, Zhang J, Li S, et al. Genomic amplification of long noncoding RNA HOTAIRM1 drives anaplastic thyroid cancer progression via repressing miR-144 biogenesis[J]. RNA Biol, 2021, 18(4): 547–562.
|
| ［24］ |
Hejazi M, Jafari T, Yari A, et al. A novel long non-coding RNA, PICSAR, promotes thyroid cancer progression through the hsa-miR-320A/hsa-miR-485/RAPGEFL1 axis[J]. Med Oncol, 2025, 42(10): 448.
|
| ［25］ |
Chen W, Yu J, Xie R, et al. Roles of the SNHG7/microRNA-9–5p/DPP4 CeRNA network in the growth and 131I resistance of thyroid carcinoma cells through PI3K/Akt activation[J]. Oncol Rep, 2021, 45(4): 3.
|
| ［26］ |
Li L, Lin X, Xu P, et al. LncRNA GAS5 sponges miR-362–5p to promote sensitivity of thyroid cancer cells to 131I by upregulating SMG1[J]. IUBMB Life, 2020, 72(11): 2420–2431.
|
| ［27］ |
Liu H, Deng H, Zhao Y, et al. LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling[J]. J Exp Clin Cancer Res, 2018, 37(1): 279.
|
| ［28］ |
Duan Y, Wang Z, Xu L, et al. LncRNA SNHG3 acts as a novel tumor suppressor and regulates tumor proliferation and metastasis via AKT/mTOR/ERK pathway in papillary thyroid carcinoma[J]. J Cancer, 2020, 11(12): 3492–3501.
|
| ［29］ |
Li Z, Gao Y, Li L, et al. Curcumin inhibits papillary thyroid cancer cell proliferation by regulating lncRNA LINC00691[J]. Anal Cell Pathol, 2022, 2022: 5946670.
|
| ［30］ |
Wang Y, Dzakah EE, Wang X. Molecular basis of backsplicing regulation and its application to manipulate circRNA levels[J]. RNA Biol, 2025, 22(1): 1–10.
|
| ［31］ |
Han P, Chen G, Zhang Q, et al. Circ_PSD3 stimulates cell proliferation, migration, invasion and epithelial to mesenchymal transition (EMT) in papillary thyroid carcinoma via the regulation of miR-145–5p/miR-338–3p/HMGB3 axis[J]. J Biochem Mol Toxicol, 2025, 39(8): e70402.
|
| ［32］ |
Dong LP, Chen LY, Bai B, et al. Circ_0067934 promotes the progression of papillary thyroid carcinoma cells through miR-1301–3p/HMGB1 axis[J]. Neoplasma, 2022, 69(1): 1–15.
|
| ［33］ |
Zheng H, Fu Q, Ma K, et al. Circ_0079558 promotes papillary thyroid cancer progression by binding to miR-26b-5p to activate MET/AKT signaling[J]. Endocr J, 2021, 68(11): 1247–1266.
|
| ［34］ |
Chen L, Zhuo D, Yuan H. Circ_100395 impedes malignancy and glycolysis in papillary thyroid cancer: involvement of PI3K/AKT/mTOR signaling pathway[J]. Immunol Lett, 2022, 246: 10–17.
|
| ［35］ |
Shu C, Wang S, Hu J, et al. CircNDST1 promotes papillary thyroid cancer progression via its interaction with CSNK2A1 to activate the PI3K-Akt pathway and epithelial–mesenchymal transition[J]. J Endocrinol Investig, 2023, 46(3): 545–557.
|
| ［36］ |
Zhou T, Li Z, Huang W, et al. Genome-wide analyses identify circAQR, a circular RNA suppressing proliferation but promoting migration and invasion in thyroid cancer[J]. NPJ Precis Oncol, 2025, 9(1): 171.
|